Mark R. Hake

Mark R. Hake

CFA

Mark R. Hake, CFA is a financial analyst and entrepreneur. He has been a Chartered Financial Analyst (CFA) for 31 years and has owned his own investment management and investment research firms that focused on value stocks, both in the U.S. and overseas.

Mark writes over 600 articles per year on stocks, cryptos, SPACs, convertibles, ETFs, and other financial securities. He has been ranked with 5 stars by TipRanks.com (under “Mark R. Hake”) with an average return of over 22% annually and #36 out of 8,116 writers. Presently he authors articles on Medium.com and other sites.

Mark also invests in public and private equities and has acted as a hedge fund manager and portfolio manager for various money management firms. He has also acted as CFO and Chief Strategy Officer for several fin-tech and software companies.

You can follow Mark on LinkedIn and on TipRanks.

Recent Articles

Zomedica Is a Winner With Its Pet Lab Product and Cash Balance

By Mark R. Hake, CFA

Zomedica is a winner with its pet lab product and cash balance. ZOM stock is worth as much as $3.61 following its Truforma product launch.

Tuscan Holdings Is Worth Significantly More In its Merger with Microvast

By Mark R. Hake, CFA

According to my calculations, THCB stock is worth between $20.92 and $30.15 per share based on its comps and projections.

Defying Buffett, American Airlines Stock Looks To Do Quite Well in 2021

By Mark R. Hake, CFA

American Airlines stock will likely do quite well in 2021. Warren Buffett's sale of AAL stock and other airline shares has turned out to be a big mistake.

Tattooed Chef Is Still Overvalued, Despite Recent Strong Growth

By Mark R. Hake, CFA

Tattooed Chef is still overvalued, despite recent strong growth. TTCF stock is still overvalued and not worth more than $15 per share, even if its forecasts come true.

Hyliion Produces Products on Target, But It Needs to Earn Revenue

By Mark R. Hake, CFA

Hyliion puts out products on target but it needs revenue. HYLN stock is worth over 16% more, provided it can hit $2 billion by 2024.

Dogecoin Remains at Best an Alt Cryptocurrency After Bitcoin and Ethereum

By Mark R. Hake, CFA

Dogecoin remains at best an alt cryptocurrency after Bitcoin and Ethereum. Dogecoin has a unique supply structure but is playing a catch-up game as an alt cryptocurrency.

Clover Health Will Have Valuation Trouble Until It Gets Profitable

By Mark R. Hake, CFA

Clover Health will have continuing valuation issues. CLOV stock won't rise until it gets profitable by 2023, but the margin is only 1%.

Workhorse Shares May Not Be Able to Recover Quickly From Postal Loss

By Mark R. Hake, CFA

Workhorse shares may not be able to recover quickly from the USPS modernization contract loss. WKHS stock is a falling knife at this point, especially until analysts rerate the stock.

Palantir Grows Into Its High-Priced Valuation

By Mark R. Hake, CFA

Palantir grows into its high-priced valuation. PLTR stock is likely potentially undervalued, at least over the long-term outlook.

Stellar Lumens Gains Alt-Crypto ‘Cred’ As Central Banks Eye Versatility

By Mark R. Hake, CFA

XLM is increasing in popularity as an alt cryptocurrency. Stellar Lumens is looking to act as a central bank digital currency throughout the world.

Load More